hotspot -WSS

hotspot

author：comprehensive 2025-09-27 23:00:59 - browse：1847

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Readout LOUD podcast: ESMO highlights & Roivant's big deal

hotspot

WSS

Key Senate panel to consider PBM, drug pricing reform package

Coloradans with cystic fibrosis could lose access to Trikafta

Quicker fix for pulse oximeters urged during FDA public meeting

Vertigo drug brings hope for rare neuron disorder, Niemann

Life sciences investors close nearly $6 billion in new funds

Kidney transplant patients stopped immunosuppressants in trial

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Do digital therapeutics have a future in medicine?

Walensky prepares to leave CDC — and Congress — behind

Do digital therapeutics have a future in medicine?

After affirmative action ruling, medical educators look to 'holistic review'

Medicare proceeds with plan to claw back hospital funds

Medical leaders decry Supreme Court decision on affirmative action

What is microchimerism and how does it affect maternal health?

How one medical school became remarkably diverse

General Catalyst, Summa Health deal will turn on physician buy

entertainment

Juul spent big to court Black leaders to promote its e

Do digital therapeutics have a future in medicine?

Live blog: Hearing on CRISPR

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Explaining an after

Readout LOUD podcast: ESMO highlights & Roivant's big deal

entertainment

hotspot

leisure time

hotspot